Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells

Conditions:   Thalassemia, Beta;   Thalassemia Major Intervention:   Biological: VGB-Ex01 Sponsors:   Institute of Hematology & Blood Diseases Hospital;   Shanghai Vitalgen BioPharma Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials